NewsBenzinga라이프록 테크놀로지스, 3분기 주당순손실 0.03달러로 전년 대비 0.10달러에서 개선, 매출 252만 2천 달러로 전년 대비 225만 7천 달러에서 증가 라이프록 테크놀로지스, 3분기 주당순손실 0.03달러로 전년 대비 0.10달러에서 개선, 매출 252만 2천 달러로 전년 대비 225만 7천 달러에서 증가 Benzinga 2026.11.16 14:35 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'US Presses UN Agency Over Taiwan Flight Restrictions, China Hits Back' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen